(Q37846672)

24 August 2017

1 reference

title

Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir (English)

1 reference

24 August 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

Srinivasan Ramanathan

1

1 reference

24 August 2017

Anita A Mathias

2

1 reference

24 August 2017

Polina German

3

1 reference

24 August 2017

Brian P Kearney

4

1 reference

24 August 2017

publication date

1 April 2011

1 reference

Clinical Pharmacokinetics

24 August 2017

published in

1 reference

24 August 2017

volume

50

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

229-244

1 reference

https://scigraph.springernature.com/pub.10.2165/11584570-000000000-00000

24 August 2017

exact match

0 references

cites work

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Elvitegravir: a new HIV integrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

HIV drug development: the next 25 years

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Emerging pharmacology: inhibitors of human immunodeficiency virus integration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Cations in the didanosine tablet reduce ciprofloxacin bioavailability.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Pharmacokinetic interaction between ritonavir and didanosine when administered concurrently to HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Clinical pharmacokinetics and pharmacodynamics of etravirine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Maraviroc: in vitro assessment of drug-drug interaction potential

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584570-000000000-00000

Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients

21 January 2018

1 reference

12 December 2020

Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine.

1 reference

12 December 2020

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

1 reference

12 December 2020

Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137

1 reference

12 December 2020

Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients

1 reference

12 December 2020

Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir

1 reference

12 December 2020

10.2165/11584570-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1029943496

0 references

1 reference